Liquid Embolic Agent Market By Product Type (Cyanoacrylate-based Liquid Embolics, Ethylene Vinyl Alcohol (EVOH)-based Embolics, Precipitating Hydrophobic Injectable Liquid, Iodized Oil-based Embolics, Hydrogel-based Embolics, Novel Polymer-based Agents), By Vascular Territory (Neurovascular, Peripheral Vascular, Visceral Vascular), By Mechanism of Action (Polymerization-based Solidification, Precipitation-based Solidification, Oil-based Viscosity Embolization), By Delivery Method (Microcatheter-based Delivery, Balloon-assisted Delivery, Direct Puncture Delivery), By Application (Cerebral Arteriovenous Malformations (AVMs), Dural Arteriovenous Fistulas (DAVFs), Intracranial Aneurysms, Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma, Others), and By End-User (Hospitals, Ambulatory Surgical Centers (ASCs), Specialized Neurovascular Centers, Cancer Treatment Centers, Others), Global Market Size, Segmental Analysis, Regional Overview, Company Share Analysis, Leading Company Profiles, and Market Forecast, 2025 – 2035.

---

What trends will shape the Liquid Embolic Agent Market in the coming years?

The Liquid Embolic Agent Market accounted for USD 287.5 Million in 2024 and USD 315.99 Million in 2025 is expected to reach USD 812.92 Million by 2035, growing at a CAGR of around 9.91%between 2025 and 2035. The Liquid Embolic Agent Market will be influenced by increasing practices of the application of minimally invasive neurovascular and oncology procedures, which would continue increasing due to an increase in cases of aneurysms, AVMs, and cancer. Improved next-generation embolic materials (e.g., non-adhesive, radiopaque, and so-called controlled-viscosity agents) will increase precision and safety.

Clinical applications will expand as more advanced applications occur in complex tumor embolization and as more applications appear in emergency hemorrhage control. The combination of microcatheter technologies and imaging inventions will enhance the accuracy of delivery. There will be a robust growth in the emerging markets, especially in Asia-Pacific, because of the increase in healthcare infrastructure and the growing interventional radiology.

What do industry experts say about the Liquid Embolic Agent market trends?

“We are excited to enlarge our offer in the treatment of arteriovenous malformations with Magic Glue. This cyanoacrylate glue offers new features compared to the historical glues on the market, such as delayed polymerisation and less adhesion to the microcatheter.”

• Pascal Girin, CEO & President of Balt International.

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the Liquid Embolic Agent market?

How will the growing neurovascular disorders boost demand for advanced embolic treatment?

The Liquid Embolic Agent Market is gaining traction because strokes, brain abnormalities, and arteriovenous malformations are on the increase worldwide. A recent study conducted by the World Health Organization (WHO) on neurological health, which was sponsored by governments, estimated that in 2021, over 3.4 billion people were living with at least one neurological disorder, with stroke as one of the leading causes of disability and death. This growing disease burden is contributing to the demand for new advanced, least invasive treatment modalities of embolic therapies that provide a selective obstruction and controlled low-dose release with deep vascular infiltration for complicated neurovascular diseases.

The use of liquid embolic agents is becoming a favorable option because it offers treatment in difficult lesions with minimal risk of surgery. Procedural success rates are further being augmented by the growing clinical expertise, catheter system delivery system improvement, and real-time imaging. The growth of specialized neurointerventional hospitals and an improved reach in the modern healthcare infrastructure are also stimulating the expansion. Widely used incentive policies, such as favorable reimbursement policies in several developed countries. The increased complications of the disease, advancing technology, and expanding clinical applications are strongly establishing liquid embolic agents as a strategic part of advanced neurovascular care. It is likely to remain such that it keeps shaping the market path ahead.

Can the rising adoption of minimally invasive interventions accelerate market penetration across multiple clinical areas?

The Liquid Embolic Agent Market is a growing market that is being encouraged by the increase in use of minimally invasive interventions within a wide spectrum of clinical domains. According to U.S. government data, minimally invasive surgery procedures comprised 11.2% of inpatient operating-room surgery in 2018, continuing to maintain the same percentage as the previous year (11.1 percent), but with an even greater share in ambulatory care settings, rising to 18% in 2018 after having stood at 17.4% in 2017. This constant expansion indicates a healthcare trend towards less invasive methods that minimize surgical trauma, medically lessen hospitalization, and help a person to recover quicker.

The liquid embolic agents perfectly fit into this trend, as they provide a highly precise vascular occlusion for neurovascular procedures, oncology, trauma, and peripheral vascular procedures. In further support of their use, there has been an enhancement in the area of catheter-based forms of delivery systems and also in real-time imaging that contributes to improved success rates and control of the procedures. The availability of trained specialists in interventional radiology and specialized interventional centers is increasing access to such treatments. Also, positive reimbursement policies in the developed healthcare settings are stimulating broader clinical use. This medical innovation, efficient clinical performance, and benevolence of benefits to the patient are increasing the speed of market penetration across various areas of treatment.

How might high procedural costs limit adoption in lower-income and developing healthcare systems?

The Liquid Embolic Agent Market has an adoption rate problem in low-income and developing health care systems because of the high cost of procedures involved in the case of advanced embolization treatments. These are costly processes that necessitate the use of coated liquid embolic agents, specialized microcatheters, highly resolved imaging units, and trained interventional radiologists, which increase the overall costs of the treatment significantly.

In most low-resource countries, few health care budgets and available funding for other priority public health care hinder investments in such expensive measures. Both patients and their dependents incur high costs, often paying the cost out-of-pocket, which makes access financially unaffordable. Also, reimbursement is completely lacking or insufficient in various developing areas, which is yet another drawback to adoption. The expense of the taxes on imports of medical devices and the cost of distributing medical devices can also increase the prices and make them unaffordable to the local hospitals. Consequently, the facilities can choose their cheaper yet less effective treatment. This reduces the infiltration of sophisticated liquid embolic agents, making their advantages available to the richer urban areas or even to secluded hospitals. This will be the way to solve these barriers: price, local production, and government subsidies, which will be necessary to make more people have access to fair provision.

Will expanding cancer-related embolization procedures create significant demand in oncology intervention markets?

The Liquid Embolic Agent Market is experiencing increasing demand for the product in embolization related to cancer due to increasing cancer rates around the world, which are showing an alarming surge. As stated in U.S. government statistics, 1,851,238 new cases of cancer have been recorded in 2022, which is a reason to employ the most progressive approaches to treatment. Embolization is also becoming more and more used in the treatment of hepatocellular carcinoma, colorectal metastases, and renal cell carcinoma to occlude the blood supply to a tumor before surgery or as a palliative treatment.

In such situations, liquid embolic agents become especially suitable since they can get deep into the tumor vasculature and have the capability of selectively and sustainably occluding the tumor vasculature. Such interventions have a limited systemic toxicity as opposed to standard chemotherapy and increase local control. There is increased accuracy and safety in administering embolic drugs through the use of good imaging guidance, like CT and MRI. The therapies are becoming more accessible as interventional radiology, oncology teams, and dedicated cancer treatment facilities grow. This trend is also boosted by the growth of cancer awareness, improved screening programs, and patient preference for a minimally invasive procedure. Consequently, liquid embolic agents are developing into an indispensable part of the contemporary oncology interventional activities in the world today.

How can emerging markets drive growth through infrastructure expansion and skilled workforce development?

Incorporation in the emerging markets is, in turn, becoming a key factor of growth in the liquid embolic agent market as expansion of healthcare infrastructures and training of skilled workforces are gaining momentum in the emerging markets. India has seen an upward trend in the number of medical colleges, increasing towards 731 colleges by 2024, starting with 387 in 2014, with significant increases in the annual number of medical seats assigned, which can be evaluated as high progress towards developing a qualified clinical workforce able to perform complex procedures. Although there is a shortage of active doctors and nurses in numerous countries, which is not sufficient compared to the WHO-recommended number, the gap between them is gradually decreasing with increased training capacity. Meanwhile, hospitals are getting upgraded to the latest MRI and CT, hybrid operating rooms, and the latest in interventional radiology suites to perform very accurate embolization practices.

The new facilities of the neurology and oncology departments are emerging in the tier-2 and -3 cities, which can be discussed as the expansion of the available commands beyond big cities. Interventional radiology is a specialized training program that is bringing forth more competent people who can provide these treatments. Collaborations of the public and the private partnerships are making it possible to fast-track the development of diagnostic and treatment infrastructure. Such an increase in the capabilities of the facilities and the growing number of trained specialists is resulting in an increased availability of advanced liquid embolic therapeutics. Consequently, the demand is increasing for neurovascular, oncology, and trauma care in new healthcare markets.

What are the key market segments in the Liquid Embolic Agent industry?

Based on the product type, the Liquid Embolic Agent Market is classified into Cyanoacrylate-based Liquid Embolics, Ethylene Vinyl Alcohol (EVOH)-based Embolics, Precipitating Hydrophobic Injectable Liquid, Iodized Oil-based Embolics, Hydrogel-based Embolics, and Novel Polymer-based Agents. The marketplace is dominated by EVOH-based embolics, Onyx and Squid, which are gaining popularity on the grounds of lack of adhesiveness, providing good radiopacity and controlled injection properties, and hence mostly finding significance in complex neurovascular procedures. The cyanoacrylate-based embolics, such as n-BCA, are still used in cases involving rapid occlusion of vessels because they are fast polymerizing and stick quite effectively in AVMs.

PHIL (Precipitating Hydrophobic Injectable Liquid) is becoming popular due to its decreased inflammatory effect and the lack of ensuring tantalum mixing, making it easier to prepare. Embolics such as Lipiodol, which are based on iodized oil, have limited application in oncology procedures, particularly in the procedure of chemoembolization in liver cancer. Hydrogel-based embolics are an analogous new faction, with expansion-based blockage sans heat or chemical reaction. New polymer-based agents are being developed to integrate flow control, biocompatibility, and long-term stability. The market, in general, is changing into next-generation, precision formulations, radiopaque, and good safety and clinical outcomes.

Based on the application, the Liquid Embolic Agent Market is classified into Cerebral Arteriovenous Malformations (AVMs), Dural Arteriovenous Fistulas (DAVFs), Intracranial Aneurysms, Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma, and Others. Treatment of cerebral arteriovenous malformations (AVMs), dural arteriovenous fistulas (DAVFs), and intracranial aneurysms categorize the application-based liquid embolic agent market leaders due to the increasing incidence of stroke and improving neurointerventional procedures.

The use of oncology is growing, with applications like hepatocellular carcinoma (HCC) and renal cell carcinoma being more successful because of tumor devascularization before surgery or in the form of palliative treatment. There is an uptake of peripheral vascular disorder therapies such as uterine fibroid embolization (UAE), pelvic congestion syndrome, and management of gastrointestinal bleeds due to their low invasive nature. When it comes to trauma and emergency care, the application of liquid embolics plays an incredibly critical role in making use of emergency hemorrhage control, most importantly when it comes to postpartum or internal bleeding. Their versatility is attributed to the increasing suitability of multi-territory embolization procedures. The development of imaging-guided delivery is expanding the treatment area. In general, the applications have been expanding outside the neurovascular to oncology, emergency, and peripheral vascular applications, increasing market demand.

Which regions are leading the Liquid Embolic Agent market, and why?

The North America Liquid Embolic Agent Market is leading due to the greater usage of advanced neurointerventional and cancer treatment procedures, well-established medical facilities, and the availability of major market players like Medtronic, Stryker, and Balt USA. Early FDA approvals of next-generation embolic agents and the presence of large pools of skilled interventional radiologists and neurosurgeons are other advantages of the region.

Increased occurrence of stroke, brain aneurysms, AVMs, and liver cancer initiates the need for liquid embolics both in hospitals and in special cases. There is much R&D and clinical trial investment that increases the growth of innovation and expansion in products. Utilization is also encouraged by reimbursements for the minimally invasive procedures. All in all, North America has technological superiority, clinical experience, and a regulatory environment, and is therefore the main hub of the global markets where liquid embolic agents are utilized.

The Asia Pacific Liquid Embolic Agent Market is growing due to the high rate of growth in the healthcare infrastructure, medical imaging facilities, and interventional radiology work. Cyber nations like China, India, Japan, and South Korea are reporting an increasing rate of neurovascular disorders, liver cancer incidence, and trauma-associated interventions, fostering demand for minimally invasive embolization procedures.

Government policies of upgrading hospitals, the education of specialists, and the availability of access to advanced medical devices are boosting the implementation process. The increased enlightenment among doctors concerning the advantages of liquid embolics in comparison with the conventional pillars in surgery is enhancing application as well. Further medical tourism in Asia is also giving a boost to the supply of high-end embolization therapies. As access and procedures from the Asian-Pacific have been improving, combined with increased access to expertise, it will emerge as an impressive proponent of future market growth.

What does the competitive landscape of the Liquid Embolic Agent market look like?

The Liquid Embolic Agent Market is the intensity of competition in the atmosphere and is determined by the prominent presence of key players, including Medtronic, Johnson & Johnson, Terumo/MicroVention, Balt International, Sirtex Medical, Arsenal Medical, Meril, and Boston Scientific. The Onyx system used by Medtronic is still considered one of the gold standards in neurovascular embolization, especially when it comes to the management of cerebral AVM and aneurysm. The Squid and PHIL systems provided by Terumo have their merits because they feature superior radiopacity, and their viscosity is optimized to navigate vessels with precision. Balt International still has to enlarge its cost-competitive solutions, particularly in peripheral indications. Sirtex Medical specializes in novel peripheral hemorrhage therapy, like its LAVA system.

Arsenal Medical is also becoming a pioneer in next-generation technology through NeoCast, which is available with h solvent-free formulation and controlled flow to ensure more safety. Increasing demand for minimally invasive treatments in neurovascular, oncology, and trauma markets is behind the innovation. Clinical trial progression and strategic alliances are still major weapons of competition. On 21 February 2025, the company Arsenal Medical reported the completion of the first cohort of the EMBO 02 clinical trial of NeoCast in the treatment of chronic subdural hematoma. Preliminary data shows high safety, feasibility, and excellent distal penetration, which marks NeoCast as a game changer in the competition in comparison to the older liquid embolic agents.

Liquid Embolic Agent Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Which recent mergers, acquisitions, or product launches are shaping the Liquid Embolic Agent industry?

• In July 2025, at the Society of Neurointerventional Surgery (SNIS) 2025 Annual Meeting, late-breaking data from the EMBO-02 study, presented by Arsenal Medical, revealed promising results for NeoCast, a new liquid embolic agent, in the treatment of chronic subdural hematoma (cSDH). The study highlighted that NeoCast injections were pain-free, leading to rapid hematoma resorption. Specifically, 100% target vessel occlusion was achieved with no off-target embolization or device-related adverse events. The results also indicated that 60% of patients experienced complete hematoma resolution at three months, increasing to 90% at six months.
• In May 2025, Merit Medical Systems finalized the acquisition of Biolife Delaware, LLC, for approximately $120 million. Biolife is known for its StatSeal® and WoundSeal® hemostatic devices. This strategic move expands Merit's interventional radiology (IR) portfolio and strengthens its position in post-procedure care for embolization. The acquisition includes Biolife's existing liabilities and was funded entirely in cash.
• In February 2025, Arsenal Medical completed enrollment for the initial cohort (10 patients) of its EMBO-02 feasibility study evaluating NeoCast for chronic subdural hematoma (cSDH) treatment via middle meningeal artery embolization. The study, conducted across three Australian sites, focused on NeoCast, a non-adhesive, solvent-free agent designed for deep penetration. All patients in the initial cohort met the safety and feasibility endpoints of the study.

Report Coverage:

By Product Type

• Cyanoacrylate-based Liquid Embolics
• Ethylene Vinyl Alcohol (EVOH)-based Embolics
• Precipitating Hydrophobic Injectable Liquid
• Iodized Oil-based Embolics
• Hydrogel-based Embolics
• Novel Polymer-based Agents

By Vascular Territory

• Neurovascular
• Peripheral Vascular
• Visceral Vascular

By Mechanism of Action

• Polymerization-based Solidification
• Precipitation-based Solidification
• Oil-based Viscosity Embolization

By Delivery Method

• Microcatheter-based Delivery
• Balloon-assisted Delivery
• Direct Puncture Delivery

By Application

• Cerebral Arteriovenous Malformations (AVMs)
• Dural Arteriovenous Fistulas (DAVFs)
• Intracranial Aneurysms
• Hepatocellular Carcinoma (HCC)
• Renal Cell Carcinoma
• Others

By End-User

• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Specialized Neurovascular Centers
• Cancer Treatment Centers
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Medtronic plc
• Johnson & Johnson Services, Inc.
• Terumo Corporation
• MicroVention, Inc.
• Balt Extrusion S.A.S.
• Stryker Corporation
• Sirtex Medical Pty Ltd
• Arsenal Medical, Inc.
• Merit Medical Systems, Inc.
• Guerbet Group
• Penumbra, Inc.
• Cook Medical LLC
• Inari Medical, Inc.
• Shape Memory Medical Inc.
• MicroPort Scientific Corporation

Frequently Asked Questions (FAQs)